← All Profound Medical CORP filings

Profound Medical CORP 8-K filings

NASDAQ
PROF
Profound Medical CORP
8-K: Profound Medical's TULSA Procedure Shows Superior Post-Operative Outcomes Compared to Robotic Prostatectomy in CAPTAIN Trial
Profound Medical's TULSA procedure demonstrates statistically significant improvements in post-operative experience compared to robotic radical prostatectomy in the CAPTAIN trial.
NASDAQ
PROF
Profound Medical CORP
8-K: Profound Medical Corp. Aims to Establish TULSA-PRO as Mainstream Prostate Treatment Option
Profound Medical Corp. is positioning its TULSA-PRO system as a leading treatment for prostate ablation, both for malignant and benign conditions, highlighting clinical trial results, patient satisfaction, and new AI-powered software enhancements.
NASDAQ
PROF
Profound Medical CORP
8-K: Profound Medical Corp. Announces Notice of Annual and Special Meeting of Shareholders
Profound Medical Corp. has announced the Notice of its 2025 Annual and Special Meeting of Shareholders to be held on May 14, 2025, along with the Management Information Circular.
NASDAQ
PROF
Profound Medical CORP
8-K: Profound Medical Announces Strong Q4 Revenue Growth and Provides Full Year 2024 Results
Profound Medical reports a 108% revenue increase in Q4 2024 compared to Q4 2023, driven by recurring revenue and capital equipment sales, while also announcing an amendment to its credit agreement with CIBC.
NASDAQ
PROF
Profound Medical CORP
8-K: Profound Medical Announces Strong Preliminary Revenue Growth and Transition to U.S. GAAP Reporting
Profound Medical reports preliminary unaudited revenue growth of 105-110% year-over-year for the fourth quarter of 2024 and announces a transition to U.S. GAAP reporting.